Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
Propanc Biopharma (Nasdaq: PPCB) entered a securities purchase agreement with Hexstone Capital for a private placement of up to $100.0 million in Series C convertible preferred stock to support a digital asset acquisition strategy and accelerate R&D. The company received an initial $1.0 million on closing via 100 Series C shares with an initial stated value of $10,000 each.
Propanc issued 9,900 warrants exercisable immediately for one preferred share at $10,000 per share (up to $99.0 million); warrants expire in 12 months. Company expects PRP to enter a First‑In‑Human study in H2 2026. Monthly call feature allows up to 500 warrants to be called per month at $0.01.
Propanc Biopharma (Nasdaq: PPCB) ha stipulato un accordo di acquisto di titoli con Hexstone Capital per una private placement fino a $100.0 million in azioni privilegiate convertibili di Serie C per supportare una strategia di acquisizione di asset digitali e accelerare la Ricerca & Sviluppo. L'azienda ha ricevuto inizialmente $1.0 million al closing tramite 100 azioni di Serie C con un valore nominale iniziale di $10,000 ciascuna.
Propanc ha emesso 9,900 warrants exercitabili immediatamente per una azione privilegiata al $10,000 per azione (fino a $99.0 million); i warrant scadono in 12 mesi. L'azienda prevede che PRP entri in uno studio First‑In‑Human nel secondo semestre del 2026. La funzione di call mensile consente di richiamare fino a 500 warrant al mese al prezzo di $0.01.
Propanc Biopharma (Nasdaq: PPCB) entró en un acuerdo de compra de valores con Hexstone Capital para una colocación privada de hasta $100.0 millones en acciones preferentes convertibles de Serie C para apoyar una estrategia de adquisición de activos digitales y acelerar la I+D. La empresa recibió un pago inicial de $1.0 millón al cierre mediante 100 acciones de Serie C con un valor nominal inicial de $10,000 cada una.
Propanc emitió 9,900 warrants exercitables de inmediato por una acción preferente a $10,000 por acción (hasta $99.0 millones); los warrants vencen en 12 meses. La compañía espera que PRP entre en un estudio First‑In‑Human en la segunda mitad de 2026. La característica de llamada mensual permite llamar hasta 500 warrants por mes a $0.01.
Propanc Biopharma (Nasdaq: PPCB)는 Hexstone Capital과 비공개 배치 계약을 체결하여 디지털 자산 인수 전략을 지원하고 R&D를 가속화하기 위해 시리즈 C 전환 우선주를 최대 $100.0 million 규모로 발행합니다. 거래 종결 시 초기 $1.0 million을 현금으로 수령했으며, 초기 명목가치는 $10,000인 100주 Series C 주식으로 지급됩니다.
Propanc는 9,900 개의 워런트를 즉시 행사 가능하게 발행했으며, 한 주당 우선주 1주에 해당하는 행사 가격은 $10,000이고 총액은 최대 $99.0 million까지입니다; 워런트의 만료 기간은 12개월입니다. 회사는 PRP가 2026년 하반기에 First‑In‑Human 연구를 시작할 것으로 기대합니다. 월별 콜 기능으로 매월 최대 500개 워런트를 $0.01에 호출할 수 있습니다.
Propanc Biopharma (Nasdaq: PPCB) a conclu une accord d'achat de titres avec Hexstone Capital pour une levée privée allant jusqu'à $100.0 millions en actions privilégiées convertibles de série C afin de soutenir une stratégie d'acquisition d'actifs numériques et d'accélérer la R&D. L'entreprise a reçu un versement initial de $1.0 million lors de la clôture via 100 actions de Série C ayant une valeur nominale initiale de $10,000 chacune.
Propanc a émis 9,900 warrants immédiatement exerçables pour une action privilégiée à $10,000 par action (jusqu'à $99.0 million); les warrants expirent dans 12 mois. La société prévoit que PRP entrera dans une étude First‑In‑Human au cours du second semestre 2026. La fonction d'appel mensuel permet d'appeler jusqu'à 500 warrants par mois à $0.01.
Propanc Biopharma (Nasdaq: PPCB) hat mit Hexstone Capital eine Wertpapierkaufvereinbarung abgeschlossen für eine private Platzierung von bis zu $100.0 million in Series-C-Umwandlungspräferenzaktien, um eine Strategie zum Erwerb digitaler Vermögenswerte zu unterstützen und F&E zu beschleunigen. Das Unternehmen erhielt bei Closing eine anfängliche Zahlung von $1.0 million über 100 Series-C-Anteile mit einem anfänglichen Nennwert von $10,000 je Aktie.
Propanc emittierte 9,900 Warrants, sofort ausübbar für eine Vorzugsaktie zu $10,000 pro Aktie (bis zu $99.0 million); Warrants verfallen in 12 Monaten. Das Unternehmen erwartet, dass PRP im 2. Halbjahr 2026 eine First‑In‑Human-Studie beginnt. Die monatliche Call-Funktion erlaubt es, bis zu 500 Warrants pro Monat zu einem Preis von $0.01 zu callen.
Propanc Biopharma (ناسداك: PPCB) أبرمت اتفاقية شراء أوراق مالية مع Hexstone Capital لعمليات طرح خاص حتى $100.0 مليون من الأسهم الممتازة القابلة للتحويل من الفئة C لدعم إستراتيجية الاستحواذ على أصول رقمية وتسريع البحث والتطوير. تلقت الشركة دفعة ابتدائية قدرها $1.0 مليون عند الإغلاق عبر 100 سهم من فئة Series C بقيمة اسمية ابتدائية قدرها $10,000 لكل سهم.
أصدرت Propanc 9,900 warrants قابلة للممارسة فورًا لسهم ممتاز واحد بسعر $10,000 للسهم (حتى $99.0 مليون دولار)؛ تنتهي صلاحية warrants خلال 12 شهراً. وتتوقع الشركة أن تبدأ PRP في دراسة First‑In‑Human في النصف الثاني من عام 2026. تسمح خاصية الاتصال الشهري بسحب حتى 500 warrants شهرياً بسعر $0.01.
- Initial cash received: $1.0M on closing
- Financing capacity: up to $100M in preferred stock
- Warrants exercisable immediately totaling up to $99M
- PRP First‑In‑Human study targeted in H2 2026
- Potential shareholder dilution from up to $99M in warrants
- Warrants expire in 12 months, concentrating near‑term financing
- Monthly call may convert up to $5M of preferred stock per month
Insights
Deal provides near-term cash and optional large funding but shifts capital strategy toward volatile digital assets and creates substantial dilution risk.
The company received an initial
Key dependencies and risks include heavy exposure to digital asset price volatility, immediate warrant exercisability with a
Watch for concrete milestones and timelines: receipt and planned use of any additional tranches from the
Initial Investment of
MELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC ("Hexstone"), a family office that has invested in a significant number of Digital Asset Treasury (DAT) companies across a range of digital assets including BTC, ETH, SOL, DOGE, ATH, OG, and INJ. The agreement is for a private placement of up to
“We are entering a transformative phase for the Company as we work on building our digital asset base and strengthening our balance sheet, which will enable us to accelerate our unique proenzyme technology to clinical development and beyond,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Our business model will revolutionize the way we fund and grow our intellectual property portfolio, fast track our R&D processes and expand our development program so that we can target not only patients suffering from metastatic cancer from solid tumors, but several chronic diseases based upon the mechanism of action of proenzyme therapy. This is our vision. We look forward to updating you as we progress.”
Additionally, Propanc will issue 9,900 Warrants to Hexstone, each entitling the purchase of one share of Preferred Stock at
Further details can be found in the Company’s Form 8-K filed with the SEC and accessible at www.sec.gov.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to prevent recurrence and metastasis in cancer patients by targeting and eradicating cancer stem cells through the activation of proenzymes. The Company’s lead product candidate, PRP, is designed to target the root cause of cancer proliferation and spread.
For more information, visit: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
What financing did Propanc (PPCB) secure on November 10, 2025?
How much initial cash did Propanc (PPCB) receive from Hexstone on closing?
What are the terms of the Warrants issued to Hexstone by Propanc (PPCB)?
How much funding could Propanc (PPCB) obtain monthly through the call feature?
How does the financing affect Propanc’s clinical timeline for PRP (PPCB)?
